Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all primary cutaneous lymphomas. With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) Consensus Classification for Cutaneous Lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms were introduced. However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centers, which may be because consensus recommendations for the management of CBCL have never been published. Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the 3 main groups of CBCL. Because no systematic reviews or (randomized) controlled trials were available, these recommendations are mainly based on retrospective studies and small cohort studies. Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state-of-the-art management as currently practiced in major cutaneous lymphoma centers. They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.

European Organization for Research and Treatment of Cancer and International Society for cutaneous lymphoma Consensus recommendations for the management of cutaneous B-cell lymphomas / N.J. Senff, E.M. Noordijk, Y.H. Kim, M. Bagot, E. Berti, L. Cerroni, R. Dummer, M. Duvic, R.T. Hoppe, N. Pimpinelli, S.T. Rosen, M.H. Vermeer, S. Whittaker, R. Willemze. - In: BLOOD. - ISSN 0006-4971. - 112:5(2008), pp. 1600-1609. [10.1182/blood-2008-04-152850]

European Organization for Research and Treatment of Cancer and International Society for cutaneous lymphoma Consensus recommendations for the management of cutaneous B-cell lymphomas

E. Berti;
2008

Abstract

Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all primary cutaneous lymphomas. With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) Consensus Classification for Cutaneous Lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms were introduced. However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centers, which may be because consensus recommendations for the management of CBCL have never been published. Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the 3 main groups of CBCL. Because no systematic reviews or (randomized) controlled trials were available, these recommendations are mainly based on retrospective studies and small cohort studies. Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state-of-the-art management as currently practiced in major cutaneous lymphoma centers. They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.
English
anti-CD20 monoclonal-antibody; helicobacter-pylori infection; Who-EORTC classification; non-Hodgkins-lymphoma; concerted action BHM4-CT98-3936; Borrelia-Burgodorferi infection; polymerase-chain-reaction; follicle center lymphoma; complete remission; follow-up
Settore MED/35 - Malattie Cutanee e Veneree
Review essay
Esperti anonimi
Pubblicazione scientifica
2008
112
5
1600
1609
10
Pubblicato
Periodico con rilevanza internazionale
scopus
crossref
pubmed
Aderisco
info:eu-repo/semantics/article
European Organization for Research and Treatment of Cancer and International Society for cutaneous lymphoma Consensus recommendations for the management of cutaneous B-cell lymphomas / N.J. Senff, E.M. Noordijk, Y.H. Kim, M. Bagot, E. Berti, L. Cerroni, R. Dummer, M. Duvic, R.T. Hoppe, N. Pimpinelli, S.T. Rosen, M.H. Vermeer, S. Whittaker, R. Willemze. - In: BLOOD. - ISSN 0006-4971. - 112:5(2008), pp. 1600-1609. [10.1182/blood-2008-04-152850]
reserved
Prodotti della ricerca::01 - Articolo su periodico
14
262
Article (author)
no
N.J. Senff, E.M. Noordijk, Y.H. Kim, M. Bagot, E. Berti, L. Cerroni, R. Dummer, M. Duvic, R.T. Hoppe, N. Pimpinelli, S.T. Rosen, M.H. Vermeer, S. Whittaker, R. Willemze
File in questo prodotto:
File Dimensione Formato  
1600.full.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 400.92 kB
Formato Adobe PDF
400.92 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/436020
Citazioni
  • ???jsp.display-item.citation.pmc??? 61
  • Scopus 362
  • ???jsp.display-item.citation.isi??? 288
social impact